Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132209) titled 'Real world observational registry study evaluting efficacy and safety of Solriamfetol, a wake-promoting agent, for the treatment of OSA patients with EDS' on Sept. 10.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Obstructive sleep apnea, OSA
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-01
Target Sample Size: Solriamfetol Treatment Group:400;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=342339
Published by HT Digital Content Services w...